COVID-19 update: FDA continues to accelerate development of novel therapies for COVID-19

FDA

31 March 2020 - As part of the Trump Administration’s all-hands-on-deck approach across public, academic and private sectors to combat the COVID-19 pandemic, the U.S. FDA stood up a new program to expedite the development of potentially safe and effective life-saving treatments. 

The program, known as the Coronavirus Treatment Acceleration Program (CTAP), is using every tool at the agency’s disposal to bring new therapies to sick patients as quickly as possible, while at the same time supporting research to further evaluate whether these medical countermeasures are safe and effective for treating patients infected with this novel virus.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder